Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Larson

Showing results (151-160 of 300) with videos related to

Pageof 30
Sort By:
Nature Communications|January 22, 2014
Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticleDaniel L J Thorek, David Ulmert, Ndeye-Fatou M Diop, et al.
Clinical Nuclear Medicine|July 6, 2019
Thyroid Cancer Bone Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care CohortJessica D Kondraciuk, Samuel L Rice, Xiaosun Zhou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 12, 2006
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicityPat Zanzonico, Guenther Koehne, Humilidad F Gallardo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 5, 2003
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRIStig Palm, Richard M Enmon, Cornelia Matei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 24, 2013
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancerMary L Gemignani, Sujata Patil, Venkatraman E Seshan, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Nuclear Medicine and Biology|May 10, 2005
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitorsDarren R Veach, Mohammad Namavari, Tatiana Beresten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2012
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancerElizabeth R Dennis, Xiaoyu Jia, Irina S Mezheritskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancerMichael J Morris, Jessica Flynn, Binsheng Zhao, et al.
Pageof 30

Showing results (151-160 of 300) with videos related to

Sort By:
Pageof 30
Nature Communications|January 22, 2014
Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticleDaniel L J Thorek, David Ulmert, Ndeye-Fatou M Diop, et al.
Clinical Nuclear Medicine|July 6, 2019
Thyroid Cancer Bone Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care CohortJessica D Kondraciuk, Samuel L Rice, Xiaosun Zhou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 12, 2006
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicityPat Zanzonico, Guenther Koehne, Humilidad F Gallardo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 5, 2003
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRIStig Palm, Richard M Enmon, Cornelia Matei, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 24, 2013
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancerMary L Gemignani, Sujata Patil, Venkatraman E Seshan, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Nuclear Medicine and Biology|May 10, 2005
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitorsDarren R Veach, Mohammad Namavari, Tatiana Beresten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2012
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancerElizabeth R Dennis, Xiaoyu Jia, Irina S Mezheritskiy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancerMichael J Morris, Jessica Flynn, Binsheng Zhao, et al.
Pageof 30